Primemd Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Primemd has 18.70 million shares outstanding.
| Current Share Class | 18.70M |
| Shares Outstanding | 18.70M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.13 |
| PB Ratio | 0.01 |
| P/TBV Ratio | 0.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.20
| Current Ratio | 1.20 |
| Quick Ratio | 1.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -6.85% and return on invested capital (ROIC) is -5.51%.
| Return on Equity (ROE) | -6.85% |
| Return on Assets (ROA) | -1.82% |
| Return on Invested Capital (ROIC) | -5.51% |
| Return on Capital Employed (ROCE) | -3.50% |
| Weighted Average Cost of Capital (WACC) | -41.04% |
| Revenue Per Employee | 69,983 |
| Profits Per Employee | -81,965 |
| Employee Count | 1 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +150.00% in the last 52 weeks. The beta is -8.24, so Primemd's price volatility has been lower than the market average.
| Beta (5Y) | -8.24 |
| 52-Week Price Change | +150.00% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.16 |
| Relative Strength Index (RSI) | 33.59 |
| Average Volume (20 Days) | 11,497 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Primemd had revenue of 69,983 and -81,965 in losses. Loss per share was -0.03.
| Revenue | 69,983 |
| Gross Profit | 69,983 |
| Operating Income | -40,273 |
| Pretax Income | -81,965 |
| Net Income | -81,965 |
| EBITDA | -36,750 |
| EBIT | -40,273 |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 435,496 in cash and n/a in debt, with a net cash position of 435,496 or 0.02 per share.
| Cash & Cash Equivalents | 435,496 |
| Total Debt | n/a |
| Net Cash | 435,496 |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 1.15M |
| Book Value Per Share | 0.37 |
| Working Capital | 72,303 |
Cash Flow
| Operating Cash Flow | -13,644 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -57.55% and -117.12%.
| Gross Margin | 100.00% |
| Operating Margin | -57.55% |
| Pretax Margin | -117.12% |
| Profit Margin | -117.12% |
| EBITDA Margin | -52.51% |
| EBIT Margin | -57.55% |
| FCF Margin | n/a |
Dividends & Yields
Primemd does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -876.72% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Primemd has an Altman Z-Score of -4.51 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.51 |
| Piotroski F-Score | 1 |